Comparison of transdermal estradiol and tibolone for the treatment of oophorectomized women with deep residual endometriosis

L Fedele, Luigi Fedele, S Bianchi, Stefano Bianchi, Ricciarda Raffaelli, R Raffaelli, Zanconato G, G. Zanconato, Giovanni Zanconato
Maturitas · 1999 · vol. 32(3) , pp. 189–193 · doi:10.1016/s0378-5122(99)00032-8 · PMID:10515676 · W2071815514
article OA: closed CC0 ⤵ 50 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-21 ⓘ

This study compared the efficacy of transdermal estradiol and tibolone in treating deep residual endometriosis in oophorectomized women.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Study objectiveTo compare the effect of HRT with transdermal estradiol and that of treatment with tibolone in post-menopausal women with residual endometriosis.Materials and methods21 women with residual pelvic endometriosis after bilateral oophorectomy with or without hysterectomy were enrolled in the study and were randomized to HRT with transdermal estradiol 50 mg twice weekly (n = 10) associated with cyclic medroxyprogesterone acetate 10 mg daily in women who preserved uterus, and to treatment with tibolone 2.5 mg administered orally once a day (n = 11). The duration of both treatments was scheduled to last at least 12 months. Residual endometriosis was located in the bowel wall in four patients, in the rectovaginal septum in six and deeply in the retroperitoneal pelvic space in six. All women were symptomatic before oophorectomy.ResultsAll the women were followed for 12 months. No patient suspended therapy because of side effects. Four patients of the estradiol group experienced moderate pelvic pain during treatment compared with only one patient in the tibolone group. One patient in the estradiol group reported severe dyspareunia.ConclusionAlthough our series is very small, it seems that tibolone may be a safe hormonal treatment for post-menopausal women with residual endometriosis.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Anabolic Agents Endometriosis Estradiol Hormone Replacement Therapy Norpregnenes Administration, Cutaneous Administration, Oral Adult Anabolic Agents Endometriosis Estradiol Estradiol Female Humans Medroxyprogesterone Acetate Medroxyprogesterone Acetate Medroxyprogesterone Acetate Middle Aged Norpregnenes Ovariectomy

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (16)

Cited by (50)

Source provenance

europepmc
last seen: 2026-08-06T06:07:45.168820+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:10:24.024533+00:00
unpaywall
last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0 · commercial use OK